ViroMed Report issue

For profit Phase 2 Phase 3
Founded: Burlington NC United States (1982)
Status: Acquired by LabCorp (2001)

Organization Overview

First Clinical Trial
2007
NCT00778882
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

ViroMed Co., Ltd. | ViroMed Co., Ltd. dba VM BioPharma

Active Ingredients

Drugs in Phase 3 Trials (1)

vm202 (11 trials)

Drugs in Phase 2 Trials (2)

nl003 (1 trial)

vm106 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyotrophic Lateral Sclerosis (Phase 2)

Arterial Occlusive Diseases (Phase 2)

Coronary Artery Disease (Phase 2)

Diabetic Foot (Phase 3)

Diabetic Neuropathies (Phase 3)

Foot Ulcer (Phase 3)

Granuloma (Phase 2)

Granulomatous Disease, Chronic (Phase 2)

Heart Diseases (Phase 2)

Infarction (Phase 2)

Ischemia (Phase 2)

Motor Neuron Disease (Phase 2)

Myocardial Infarction (Phase 2)

Myocardial Ischemia (Phase 2)

Pain (Phase 3)

Peripheral Arterial Disease (Phase 2)

Peripheral Nervous System Diseases (Phase 3)

Peripheral Vascular Diseases (Phase 2)

Sclerosis (Phase 2)

Ulcer (Phase 3)

Vascular Diseases (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 13
  • # of Trial APIs: 3